$MRNA has caught the attention of investors after its stock experienced a notable boost following news of significant funding directed at developing a bird flu vaccine. The company's shares surged by 5%, driven by a $590 million grant awarded by the U.S. Department of Health and Human Services (HHS). This funding aims to accelerate the creation of a vaccine based on cutting-edge mRNA technology.